Orange Book TE codes: how to tell whether a generic can actually be substituted

A pharmacy receives a prescription for a brand-name drug. A generic is in stock. The pharmacist pulls up the FDA Orange Book, sees a therapeutic equivalence code, and has to decide: substitute, or dispense as written? For an AB-rated product the answer is usually yes. For a BX code the answer is no — FDA has not determined the product to be therapeutically equivalent, and substitution is off the table. For a BC code the answer is also no, and for a single-source product with no code at all, there is nothing to substitute. The code is a two-character field, but the dispensing decision behind it carries clinical, legal, and reimbursement weight.

The Orange Book's therapeutic equivalence (TE) code is the single field a pharmacy, a generics team, and a payer all key on when deciding whether one approved product can stand in for another. FDA publishes the codes as scientific advice — but the actual authority to substitute is state law, layered on top. A product that is AB-rated in the Orange Book can still be non-substitutable in a state with a restrictive formulary, or substitutable-but-mandatory in a state that requires the switch. Reading the code correctly is necessary; reading it alone is not sufficient.

This article is a substitution-decision workflow for pharmacy operations, generics strategy, and market-access teams. It decodes every TE code you will actually encounter, explains the AB1/AB2/AB3 grouping that confuses most first-time readers, walks the state-law overlay, and shows how to do a real Orange Book lookup with worked examples. It is written for dispensing pharmacists, pharmacy operations leaders, generics commercial teams planning launch substitution economics, and payer pharmacy staff setting formulary substitution rules. For the aggregate TE-code distribution — how many products carry each code, the share that is single-source, and which ingredients face the densest generic competition — see the companion Orange Book therapeutic equivalence by the numbers analysis; this article stays on the dispensing decision a single code drives.

What therapeutic equivalence means in the Orange Book

The Orange Book — formally Approved Drug Products with Therapeutic Equivalence Evaluations — lists drug products approved under Section 505 of the FD&C Act and assigns TE codes to the multisource ones. FDA defines two products as therapeutically equivalent when they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and when they can be expected to have the same clinical effect and safety profile under the conditions in the labeling.

Two prerequisites sit underneath that definition:

• Pharmaceutical equivalence — identical dosage form and route, identical amounts of the identical active ingredient, identical strength.
• Bioequivalence — no significant difference in the rate and extent to which the active ingredient becomes available at the site of action.

The TE code distills both judgments into two characters. The first letter tells you whether FDA considers the product therapeutically equivalent to other pharmaceutically equivalent products. The second letter tells you the basis for that evaluation, usually the dosage form.

The scale of what is — and isn't — coded

Not every product in the Orange Book gets a TE code. In the Orange Book product data analyzed for this article (covering roughly 48,200 approved product records), about 55% carry no TE code at all — these are single-source products, typically NDA brands with no approved ANDA duplicate, for which there is nothing to compare. The remaining 45% carry a TE code and are the multisource products where substitution is even a question.

Among the TE-coded products, the first-letter split is decisive: about 99.6% are A-rated (FDA considers them therapeutically equivalent) and only 0.4% are B-rated (not determined to be therapeutically equivalent). In other words, once a product is far enough along to have earned a code rather than a blank, it has almost always cleared the equivalence bar. The rare B codes are where substitution breaks down.

Decoding the TE codes

A codes — substitutable

An A as the first letter means FDA considers the product therapeutically equivalent to other pharmaceutically equivalent products. The second letter indicates the basis — generally the dosage form or whether bioequivalence problems had to be resolved:

In the data analyzed here, AB accounts for about 68% of all TE-coded products — it is overwhelmingly the code a dispensing pharmacist will see on a conventional oral generic. AP (injectable aqueous solutions) accounts for another 17%, AA for about 5%, and the remaining A codes (AT, AN, AO) are each under 3%.

B codes — not substitutable

A B as the first letter means FDA does not currently consider the product therapeutically equivalent to other pharmaceutically equivalent products. The second letter again signals the dosage-form situation:

For substitution decisions, treat any B-rated product as non-substitutable. BX is the code a pharmacist most often encounters in the B family — it means FDA does not yet have enough information to make an equivalence determination, not that the product is unsafe. BC, on extended-release forms, is a common one to flag because the molecule is familiar but the modified-release delivery is what blocks equivalence.

The AB1 / AB2 / AB3 grouping — the field most readers miss

This is where most first-time Orange Book readers get stuck. Some multisource ingredients have two or more reference listed drugs (RLDs) under the same heading — historically separate brands that were each approved as their own reference. FDA cannot collapse them into a single equivalence group without bioequivalence data bridging every pair, so it creates numbered sub-groups: AB1, AB2, AB3, AB4.

The rule is precise: products are therapeutically equivalent to each other only within the same numbered code. A product coded AB1 is substitutable for other AB1 products, but not for an AB2 or AB3 product of the same ingredient, even though all are "AB-rated." Levothyroxine sodium is the canonical example — its Orange Book entries carry codes like AB1, AB2, AB3, and AB4 across different originator brands, and a chart in the Orange Book preface maps which NDA is the reference listed drug for each number.

You can see the same pattern in a crowded ingredient like metformin hydrochloride. The Orange Book lists many manufacturers, each carrying AB, AB1, AB2, or AB3. Reading "AB" alone as "fully substitutable across the board" overstates the equivalence; the number matters. For a pharmacy building a substitution rule, the safe comparison is the full code, including the number, not just the first two letters.

The approval pathway shapes the code: ANDA vs. 505(b)(2)

The pathway a product was approved under predicts its TE code. A Section 505(j) ANDA duplicates the reference listed drug in active ingredient, strength, dosage form, and route, and an approved ANDA is by default rated A (typically AB) — which is what makes automatic pharmacy substitution possible. A Section 505(b)(2) NDA, by contrast, relies on data from a listed drug it does not fully own, and is not guaranteed an A rating. A 505(b)(2) product can land at A, but it can also receive a B code if FDA finds unresolved bioequivalence questions. For generics and access teams evaluating a competitor, the application type column (A for ANDA, N for NDA) is a quick flag: an N-coded product with a B rating entered the market without an automatic substitution pathway and depends on prescriber-level pulling, not pharmacy switching. FDA can and does revise a TE code after approval when new data arrives, so a code seen today is not guaranteed permanent.

Authorized generics and the repackager equivalence rule

One equivalence rule is easy to miss because it does not appear as a code at all. FDA's Orange Book preface states that any drug product repackaged or distributed by the applicant (or a person authorized by the applicant — that is, an authorized generic) is considered therapeutically equivalent to the applicant's own product, even if that product is single-source or coded as non-equivalent (for example, BN). Distributors and repackagers of an applicant's drug are not identified separately in the Orange Book, which is why an authorized generic can be substituted for the brand without its own distinct equivalence evaluation. For pharmacy purchasing teams, this means the absence of a separate TE-coded entry does not by itself rule out an authorized-generic equivalent that shares the brand applicant's lineage.

RLD, RS, and why both columns matter

The Orange Book lists two reference columns that drive substitution and ANDA planning:

• RLD (Reference Listed Drug) — the listed drug that an ANDA applicant duplicates; the basis for the generic.
• RS (Reference Standard) — FDA's selected comparator product for any in vivo bioequivalence studies.

In the data analyzed here, about 7,700 product rows are flagged RLD and about 4,500 are flagged RS. They are not the same. A product can be the RLD (what the generic was approved against) without being the current RS (what new generics must run bioequivalence studies against). For a generics team planning an ANDA, the RS column — not the RLD column — tells you which product to benchmark against. For a pharmacy, the RLD is the brand the generic is understood to duplicate.

The state-law overlay: where substitution actually gets decided

This is the part the TE code cannot answer on its own. FDA states explicitly that the Orange Book contains advice and does not mandate which products are purchased, prescribed, dispensed, or substituted. Therapeutic equivalence is a scientific judgment; generic substitution is a matter of state law, administered state by state. By the mid-1980s, every state had repealed its anti-substitution laws and adopted generic substitution laws instead — but the details vary widely.

Four axes determine whether an AB-rated generic actually gets substituted at a given pharmacy:

Dispense-as-Written (DAW) codes

The DAW (or "product selection") code on the claim encodes the substitution decision and travels with the adjudication. The NCPDP DAW product-selection values are:

DAW 6 is reserved and not in general use.

A DAW 1 (prescriber wrote "dispense as written") overrides substitution regardless of the TE code. A DAW 7 signals a legal barrier — narrow therapeutic index drugs, for example, are treated specially in several states because small differences in blood concentration can matter clinically, and some state laws restrict or require extra documentation for NTI substitutions even on AB-rated products.

Narrow therapeutic index (NTI) drugs: the exception to "AB means substitute"

Narrow therapeutic index drugs — warfarin, levothyroxine, phenytoin, carbamazepine, digoxin, and similar agents where small dose or blood-concentration differences can cause therapeutic failure or toxicity — are the main scientific exception to the standard AB-rating logic. FDA still assigns these products AB codes (and the numbered AB groups, as with levothyroxine), and at the federal level an AB rating is an AB rating. But because the clinical margin is thin, several states impose extra requirements on NTI substitution — prior-notification-of-switch rules, limits on switching between specific manufacturers, or prescriber-consent requirements — even when the Orange Book says the products are equivalent. For an AB-rated NTI drug, do not assume the A code alone satisfies every state's substitution rule; the NTI overlay is a separate check.

The substitution-decision workflow

For any prescription where a generic is available, run this sequence.

Step 1 — Look up the prescribed product in the Orange Book

Search the FDA Orange Book by active ingredient (the generic name) and the dosage form and strength on the prescription. Confirm the trade name, applicant, and application number match the dispensed product.

Step 2 — Read the TE code

• No code (blank) → single-source; there is no approved equivalent to substitute. Stop.
• A code (AA, AB, AN, AO, AP, AT) → FDA considers it therapeutically equivalent. Proceed, but respect any number (AB1 vs AB2).
• B code (BC, BD, BE, BN, BP, BR, BS, BT, BX, B) → not substitutable. Dispense as written.

Step 3 — Match the full numbered code

If the code is a numbered AB group (AB1, AB2, AB3, AB4), substitute only within the same number. Do not treat AB1 and AB2 as interchangeable.

Step 4 — Apply your state's substitution law

Confirm whether your state mandates or permits substitution for this product class, whether a positive or negative formulary governs it, and whether patient consent is presumed or must be explicit. Check for any NTI or product-class-specific restriction (antiepileptics, for instance, are handled specially in some states).

Step 5 — Check the DAW and plan rules

If the prescriber wrote DAW or the plan requires a specific product, that overrides substitution. Set the DAW code on the claim to reflect the actual decision.

Worked examples from the Orange Book

The clearest way to read a TE code is to watch it drive a decision. The examples below are representative Orange Book cases (codes reflect the analysis date; FDA revises codes, so verify the live record before dispensing).

The levothyroxine row is the case FDA calls out by name in the Orange Book preface: because levothyroxine has multiple reference listed drugs (Unithroid, Synthroid, Levoxyl, and Thyro-Tabs), FDA created the AB1 through AB4 groups so that a generic is substitutable only against the specific reference it was shown bioequivalent to. Reading "AB" without the number overstates the equivalence, and the same numbered-group pattern recurs in other crowded ingredients such as metformin hydrochloride.

The case that catches teams off guard is a BC product built on a familiar molecule: the active ingredient may be well known, but the extended-release delivery is what blocks equivalence. FDA does not consider different extended-release forms of the same active ingredient therapeutically equivalent unless equivalence in both rate and extent was specifically demonstrated; without that data the product is coded BC and is not automatically substitutable. A BX code is the other common trap — it means FDA does not yet have enough information to make an equivalence determination, which is a documentation gap rather than a safety finding, but the substitution outcome is the same: do not substitute.

What generics and access teams should take from this

For generics commercial teams, the TE code is the entry condition to the substitution market. A new ANDA approved with an AB rating enters a substitutable pool immediately in permissive states; an approval that lands at BX or a B code enters with no automatic substitution pathway and depends entirely on prescriber-level pulling. Planning launch substitution economics on a product that is not A-rated will systematically overstate uptake.

For payer pharmacy teams, the Orange Book is the legal basis for most state substitution rules — the formulary substitution logic should key on the full TE code (including the AB number), the RLD/RS flags, and the state-specific overlay, not on ingredient name alone. And for access teams tracking competitive erosion, the count of A-rated competitors per ingredient is the cleaner signal of price pressure than the raw count of approved ANDAs: hydrocortisone, levetiracetam, metformin, ibuprofen, and doxycycline each have dozens of distinct applicants carrying A codes, which is the real substitution-competition picture.

This article is for informational purposes only and does not constitute medical advice, legal advice, or pharmacy practice guidance for any specific entity or jurisdiction. Therapeutic equivalence codes, reference listed drugs, and state substitution laws change; always verify the current Orange Book record and your state's substitution statute before dispensing.

Last updated: June 13, 2026.

Sources

• FDA. "Orange Book Preface" (Therapeutic Equivalence Evaluations Codes, Sections 1.7–1.8). fda.gov
• FDA. "Orange Book: Frequently Asked Questions and Answers." fda.gov
• FDA. "Approved Drug Products with Therapeutic Equivalence Evaluations" (Introduction). fda.gov
• FDA. "Draft Guidance for Industry: Evaluation of Therapeutic Equivalence." fda.gov
• FDA. "Orange Book Cumulative Supplement 4, April 2026" (levothyroxine AB-code chart). fda.gov
• FDA. "Drugs@FDA Glossary of Terms" (Therapeutic Equivalence; TE Codes). fda.gov
• FDA. "Introduction of Bioequivalence for Generic Drug Product" (TE code definitions: AA, AB, BC, BD, BE, BN, BP, BR, BS, BT, BX). fda.gov
• Pasha, M. "Generic Substitution Laws and Combination Products," FDA Law Institute (FDLJ 78:2). fdli.org
• Shrank, W. et al. "The effects of state-level pharmacist regulations on generic substitution of prescription drugs," PMC. pmc.ncbi.nlm.nih.gov
• U.S. Pharmacist. "Generic-Substitution Laws." uspharmacist.com
• New York Medicaid. "Brand Less than Generic Program FAQ" (NCPDP DAW code definitions). fhsc.com
• DrugPatentWatch. "Decoding the FDA Orange Book's Therapeutic Equivalence (TE) Codes for Generic Drug Substitution Strategy." drugpatentwatch.com
• Hyman, P. "TE Codes 101: FDA Guidance Teaches Basics of Therapeutic Equivalence Codes," The FDA Law Blog, July 2022 (ANDA vs. 505(b)(2) pathway and TE rating; FDA revises codes). thefdalawblog.com